Personalized Drug Response: IMplementation and Evaluation in CKD
The PRIME-CKD program builds on breakthrough findings in the Innovative Medicine Initiative 2 program BEAt-DKD which was initiated in 2016 and identified novel biomarkers of disease progression and treatment response in patients with diabetic kidney disease.
PRIME-CKD is funded by the HORIZON Europe program and started January 2022.
GCKD is a member of the PRIME-CKD consortium.
The PRIME-CKD consortium is committed to demonstrating in the clinical setting, the utility of novel biomarkers as tools for better selection of drug therapies for patients, for use both in daily clinical practice and innovative clinical trials.